Leveraging its international network of offices, Baker McKenzie Switzerland AG assists a high-profile client roster of major pharma and biotech corporations, including Sino Biopharmaceutical, Baxter, and Bristol Myers Squibb. Jointly leading the practice, Geneva’s Olha Demianiuk is recommended for her expertise in healthcare product portfolio acquisitions, corporate reorganisations, and regulatory compliance, and Julia Schieber stands out due to her strong focus on commercial transactions concerning the supply and distribution of pharma, biotech, and medical device products in the Zurich office.
Legal 500 Editorial commentary
Key clients
- Abbott
- AbbVie
- Actelion Pharmaceuticals AG
- Adagene AG
- Alexion
- Allecra Therapeutics AG
- Araris Biotech
- Argenx SE
- Aricium
- Baitella Holding AG
Work highlights
- Advised Numab Therapeutics on its USD 1.25 billion sale of its atopic dermatitis spin-off to Johnson & Johnson.
- Advised CureVac SE on its licensing deal with GSK under which GSK has acquired full rights to develop, manufacture and commercialise mRNA candidate vaccines for influenza and COVID-19 globally.
- Advised Saudi Pharmaceutical Industries & Medical Appliances Corporation on the acquisition of 68.0% of the shares in Swiss pharmaceutical company Osmopharm S.A.
Lawyers
Next generation partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
Olha Demianiuk; Julia Schieber
Other key lawyers
Matthias Courvoisier; Peter Reinert; Serge Pannatier